Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 02, 2019 07:30 ET | Source: Otonomy, Inc.

Otonomy Announces OTIPRIO® Co-Promotion Agreement with Glenmark Therapeutics for Acute Otitis Externa Indication

SAN DIEGO, May 02, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the...
May 01, 2019 07:30 ET | Source: Otonomy, Inc.

Otonomy to Participate in SunTrust Robinson Humphrey Life Sciences Summit

SAN DIEGO, May 01, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced...
November 08, 2017 16:12 ET | Source: Otonomy, Inc.

Otonomy Reports Third Quarter 2017 Financial Results and Provides Corporate Update

SAN DIEGO, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
November 08, 2017 16:05 ET | Source: Otonomy, Inc.

Otonomy Reports Positive Results from AVERTS-2 Phase 3 Trial of OTIVIDEX™ in Patients with Ménière's Disease

Achieved primary endpoint (p value = 0.029)Company plans to meet with FDA to discuss results and clinical requirements for registrationManagement will review results during third quarter conference...
November 01, 2017 16:05 ET | Source: Otonomy, Inc.

Otonomy to Report Third Quarter 2017 Financial Results and Provide Corporate Update

SAN DIEGO, Nov. 01, 2017 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
September 13, 2017 07:30 ET | Source: Otonomy, Inc.

Otonomy Provides Business and Financial Update

Actions taken to reduce costs following suspension of OTIVIDEX™ developmentNon-commercial workforce reduced by one-thirdCurrent cash balance expected to fund company into 2020Review underway to...
May 04, 2017 16:27 ET | Source: Otonomy, Inc.

Otonomy Reports First Quarter 2017 Financial Results and Provides Corporate Update

SAN DIEGO, May 04, 2017 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
February 24, 2017 07:30 ET | Source: Otonomy, Inc.

Otonomy to Report Fourth Quarter and Full Year 2016 Financial Results and Provide Corporate Update

SAN DIEGO, Feb. 24, 2017 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...
October 07, 2016 08:00 ET | Source: Otonomy, Inc.

Otonomy Holds Investor and Analyst Day and Provides Corporate Update

SAN DIEGO, Oct. 07, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
August 01, 2016 07:30 ET | Source: Otonomy, Inc.

Otonomy Successfully Completes One-Year, Multiple-Dose Clinical Safety Trial for OTO-104 in Ménière’s Disease Patients

SAN DIEGO, Aug. 01, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...

Next Page keyboard_arrow_right